Altimmune, Inc. (ALT)

Altimmune Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	135.16	111.13	190.34	115.95	9
Short-Term Investments	62.7	73.78	0	100.01	28.28
Cash & Cash Equivalents	197.86	184.91	190.34	215.96	37.27
Cash Growth	7.00%	-2.85%	-11.86%	479.37%	8.50%
Receivables	1.11	0.17	0.43	4.61	1.02
Other Current Assets	10.66	7.73	13.36	9.69	1.1
Total Current Assets	209.63	192.81	204.13	230.26	39.39
Property, Plant & Equipment	0.65	1.08	1.45	1.06	1.8
Goodwill and Intangibles	0	12.42	12.42	12.82	12.73
Other Long-Term Assets	0.36	0.62	0.87	0.98	0.13
Total Long-Term Assets	1.01	14.12	14.74	14.86	14.66
Total Assets	210.64	206.93	218.87	245.12	54.06
Accounts Payable	2.07	4.8	2.03	0.61	0.02
Other Current Liabilities	10.07	12.25	16.24	11.41	3.9
Total Current Liabilities	12.14	17.05	18.28	12.02	3.92
Other Long-Term Liabilities	4.4	4.58	1.45	7.22	4.61
Total Long-Term Liabilities	4.4	4.58	1.45	7.22	4.61
Total Liabilities	16.54	21.64	19.73	19.24	8.54
Retained Earnings	-466.33	-377.88	-293.17	-186.42	-137.38
Comprehensive Income	-5	-5.23	-5.04	-5.04	-5.02
Shareholders' Equity	194.1	185.29	199.14	225.88	45.52
Net Cash / Debt	197.86	184.91	190.34	215.96	37.27
Net Cash / Debt Growth	7.00%	-2.85%	-11.86%	479.37%	8.73%
Net Cash Per Share	3.72	3.94	4.61	8.42	2.84
Working Capital	197.48	175.76	185.85	218.24	35.47
Book Value Per Share	3.65	3.95	4.82	8.81	3.47

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).